Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.

Inovio Pharmaceuticals Inc. closed 86.10% short of its 52-week high of $14.75, which the company achieved on April 1st.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bionoid Pharma, Inc. ("Bionoid") is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by ...

Between March 3, 2025, and March 7, 2025, Essity Aktiebolag (publ) repurchased a total of 270,000 own Class B shares (ISIN: SE0009922164) under the framework of the buyback program as resolved by the ...

Inovio Pharmaceuticals, AstraZeneca, University of Pennsylvania, HR0011-21-9-0001) for this effort. The views expressed in this press release reflect the views of the authors and do not necessarily ...

INOVIO (NASDAQ: INO) has announced that it will release its fourth-quarter and year-end 2024 financial results on March 18, ...

INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal ...